US 10150783
Heterocyclic ITK inhibitors for treating inflammation and cancer
granted A61KA61K45/06A61P
Quick answer
US patent 10150783 (Heterocyclic ITK inhibitors for treating inflammation and cancer) held by Aclaris Therapeutics, Inc. expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Aclaris Therapeutics, Inc.
- Grant date
- Tue Dec 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K45/06, A61P, A61P1/00, A61P1/04